2nd Annual Targeted Radiopharmaceuticals Summit US

R&D
2nd Annual Targeted Radiopharmaceuticals Summit US

With the space continuing its upward trajectory with more compounds moving through the clinic, it’s an exciting time to be in the targeted radiopharmaceuticals space! The Targeted Radiopharmaceuticals Summit US is retuning for its 2nd annual year this July (25 – 27) in Boston, MA. Bringing the space, a more comprehensive 3-day agenda with tracks covering the whole targeted radiopharmaceuticals landscape from discovery, translation, to clinical, late-stage progress and challenges.

We have collaborated with the leading experts in the space to form a comprehensive 3-day program to:

  • Explore the novel target selection to re-route targeted radiopharmaceuticals from a niche-label therapeutic
  • Navigate the regulation and reimbursement challenges to improve the accessibility of targeted radiopharmaceuticals
  • Review theragnostic in the clinic to exploit the two-birds-one-stone potential of TRPs
  • Discover the potential combination therapies with DDRi's and IO to unlock synergy with other modalities
  • Harness the platform technologies for optimized preclinical evaluation of drugs

All are presented by top industry players such as Clarity Pharmaceuticals, SOFIE Biosciences, Lantheus, Fusion Pharmaceuticals, Rayze Bio, Telix Pharmaceuticals, OranoMed, Actinium Pharmaceuticals, and many more.

Download the brand-new event guide here to see a full overview of 3-day content and speaker faculty.

2nd Annual Targeted Radiopharmaceuticals Summit US

 

Image
2nd-Targeted-Radiopharmaceuticals-US-2023-logo